The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salvage therapy, are needed. Herein, we evaluated the 41‐gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Triulzi, Tiziana, Bianchini, Giampaolo, Di Cosimo, Serena, Pienkowski, Tadeusz, Im, Young‐Hyuck, Bianchi, Giulia Valeria, Galbardi, Barbara, Dugo, Matteo, De Cecco, Loris, Tseng, Ling‐Ming, Liu, Mei‐Ching, Bermejo, Begoña, Semiglazov, Vladimir, Viale, Giulia, de la Haba‐Rodriguez, Juan, Oh, Do‐Youn, Poirier, Brigitte, Valagussa, Pinuccia, Gianni, Luca, Tagliabue, Elda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208076/
https://www.ncbi.nlm.nih.gov/pubmed/34816585
http://dx.doi.org/10.1002/1878-0261.13141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208076/
https://www.ncbi.nlm.nih.gov/pubmed/34816585
http://dx.doi.org/10.1002/1878-0261.13141

Ejemplares similares